369 related articles for article (PubMed ID: 32544493)
1. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
Skafi N; Fayyad-Kazan M; Badran B
Gene; 2020 Sep; 754():144888. PubMed ID: 32544493
[TBL] [Abstract][Full Text] [Related]
2. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
3. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
Padrón Á; Hurez V; Gupta HB; Clark CA; Pandeswara SL; Yuan B; Svatek RS; Turk MJ; Drerup JM; Li R; Curiel TJ
Exp Gerontol; 2018 May; 105():146-154. PubMed ID: 29326088
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
5. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
9. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
Azoury SC; Straughan DM; Shukla V
Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
[TBL] [Abstract][Full Text] [Related]
11. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
Wei J; Nduom EK; Kong LY; Hashimoto Y; Xu S; Gabrusiewicz K; Ling X; Huang N; Qiao W; Zhou S; Ivan C; Fuller GN; Gilbert MR; Overwijk W; Calin GA; Heimberger AB
Neuro Oncol; 2016 May; 18(5):639-48. PubMed ID: 26658052
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
Calabrò L; Ceresoli GL; D'Incecco A; Scherpereel A; Aerts J; Maio M
Cytokine Growth Factor Rev; 2017 Aug; 36():25-31. PubMed ID: 28736182
[TBL] [Abstract][Full Text] [Related]
13. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
14. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
Salama AK; Moschos SJ
Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
16. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
17. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoints and their inhibition in cancer and infectious diseases.
Dyck L; Mills KHG
Eur J Immunol; 2017 May; 47(5):765-779. PubMed ID: 28393361
[TBL] [Abstract][Full Text] [Related]
20. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]